Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2309 ARTÍCULOS , VIENDO DEL 211 AL 225

Natural Alkaloids as Multi-Target Compounds towards Factors Implicated in Alzheimer's Disease

Vrabec R, Blunden G, Cahlíková L.

Int J Mol Sci. 2023 Feb 23;24(5):4399. doi: 10.3390/ijms24054399.

The Effects of Momordica charantia on Type 2 Diabetes Mellitus and Alzheimer's Disease

Richter E, Geetha T, Burnett D, Broderick TL, Babu JR.

Int J Mol Sci. 2023 Feb 28;24(5):4643. doi: 10.3390/ijms24054643.

MicroRNAs and MAPKs: Evidence of These Molecular Interactions in Alzheimer's Disease

Raffaele I, Silvestro S, Mazzon E.

Int J Mol Sci. 2023 Mar 1;24(5):4736. doi: 10.3390/ijms24054736.

Status of Metabolomic Measurement for Insights in Alzheimer's Disease Progression-What Is Missing?

Yin C, Harms AC, Hankemeier T, Kindt A, de Lange ECM.

Int J Mol Sci. 2023 Mar 4;24(5):4960. doi: 10.3390/ijms24054960.

Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer's Disease

Zhong X, Na Y, Yin S, Yan C, Gu J, Zhang N, Geng F.

Molecules. 2023 Mar 3;28(5):2336. doi: 10.3390/molecules28052336.

Oxidative stress: A target to treat Alzheimer's disease and stroke

Briyal S, Ranjan AK, Gulati A.

Neurochem Int. 2023 May;165:105509. doi: 10.1016/j.neuint.2023.105509. Epub 2023 Mar 11.

Alleviating the unwanted effects of oxidative stress on Aβ clearance: a review of related concepts and strategies for the development of computational modelling

Somin S, Kulasiri D, Samarasinghe S.

Transl Neurodegener. 2023 Mar 13;12(1):11. doi: 10.1186/s40035-023-00344-2.

[Lecanemab in Alzheimer's disease: are we really before a shift in the prognosis of the disease?]

Pérez-Martínez DA.

Rev Neurol. 2023 Mar 16;76(6):185-188. doi: 10.33588/rn.7606.2023055.

The effects of microglia-associated neuroinflammation on Alzheimer's disease

Wang C, Zong S, Cui X, Wang X, Wu S, Wang L, Liu Y, Lu Z.

Front Immunol. 2023 Feb 22;14:1117172. doi: 10.3389/fimmu.2023.1117172. eCollection 2023.

TGF-β1 signalling in Alzheimer's pathology and cytoskeletal reorganization: a specialized Tau perspective

Kapoor M, Chinnathambi S.

J Neuroinflammation. 2023 Mar 13;20(1):72. doi: 10.1186/s12974-023-02751-8.

Therapeutic potential of ADAM10 modulation in Alzheimer's disease: a review of the current evidence

Khezri MR, Mohebalizadeh M, Ghasemnejad-Berenji M.

Cell Commun Signal. 2023 Mar 14;21(1):60. doi: 10.1186/s12964-023-01072-w.

Lecanamab Ushers in a New Era of Anti-Amyloid Therapy for Alzheimer's Disease

Musiek ES, McDade E, Holtzman DM.

Ann Neurol. 2023 May;93(5):877-880. doi: 10.1002/ana.26643. Epub 2023 Mar 29.

Study protocol for a phase III randomised controlled trial of Sailuotong (SLT) for vascular dementia and Alzheimer's disease with cerebrovascular disease

Karamacoska D, Chan DKY, Leung I, Liu JX, Brodaty H, Fahey PP, Bensoussan A, Chang DH.

PLoS One. 2023 Mar 15;18(3):e0265285. doi: 10.1371/journal.pone.0265285. eCollection 2023.

The action of phosphodiesterase-5 inhibitors on β-amyloid pathology and cognition in experimental Alzheimer's disease: A systematic review

Justo AFO, Toscano ECB, Farias-Itao DS, Suemoto CK.

Life Sci. 2023 May 1;320:121570. doi: 10.1016/j.lfs.2023.121570. Epub 2023 Mar 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias